In the last trading session, 1.23 million shares of the Janux Therapeutics Inc (NASDAQ:JANX) were traded, and its beta was 3.17. Most recently the company’s share price was $36.11, and it changed around -$1.69 or -4.47% from the last close, which brings the market valuation of the company to $2.09B. JANX currently trades at a discount to its 52-week high of $71.71, offering almost -98.59% off that amount. The share price’s 52-week low was $7.81, which indicates that the current value has risen by an impressive 78.37% since then. We note from Janux Therapeutics Inc’s average daily trading volume that its 10-day average is 0.87 million shares, with the 3-month average coming to 1.17 million.
Janux Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.27. If we narrow it down even further, the data shows that 0 out of 14 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended JANX as a Hold, whereas 12 deemed it a Buy, and 0 rated it as Underweight. Janux Therapeutics Inc is expected to report earnings per share of -0.45 for the current quarter.
Janux Therapeutics Inc (NASDAQ:JANX) trade information
Instantly JANX has showed a red trend with a performance of -4.47% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 45.79 on recent trading dayincreased the stock’s daily price by 21.14%. The company’s shares are currently down -32.56% year-to-date, but still down -12.59% over the last five days. On the other hand, Janux Therapeutics Inc (NASDAQ:JANX) is -22.78% down in the 30-day period. We can see from the shorts that 8.13 million shares have been sold at a short interest cover period of 7.24 day(s).
The consensus price target as assigned by Wall Street analysts is $70, which translates to bulls needing to increase their stock price by 48.41% from its current value. Analyst projections state that JANX is forecast to be at a low of $69 and a high of $100.
Janux Therapeutics Inc (JANX) estimates and forecasts
The year-over-year growth rate is expected to be 36.46%, up from the previous year.
Consensus estimates provided by 10 financial analysts predict the company will bring in an average of 490k in revenue for the current quarter. 9 analysts expect Janux Therapeutics Inc to make 1.21M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 2.46M and 1.25M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -80.09%. Forecasts for the next quarter put sales growth at -3.29%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -92.62%. Janux Therapeutics Inc earnings are expected to increase by -11.44% in 2025, but the outlook is negative -24.84% per year for the next five years.
JANX Dividends
Janux Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
Janux Therapeutics Inc (NASDAQ:JANX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 7.22% of Janux Therapeutics Inc shares, and 87.76% of them are in the hands of institutional investors. The stock currently has a share float of 94.60%. Janux Therapeutics Inc stock is held by 254.0 institutions, with RA CAPITAL MANAGEMENT, L.P. being the largest institutional investor. By 2024-06-30, it held 18.6864% of the shares, which is about 9.17 million shares worth $383.95 million.
FMR LLC, with 15.8566% or 7.78 million shares worth $325.8 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Nov 30, 2024. The former held 1.31 shares worth $47.32 million, making up 2.50% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 1.0 shares worth around $36.17 million, which represents about 1.91% of the total shares outstanding.
